ORIGINAL ARTICLE Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting Ori Magen, Jacob G. Waxman, Maya Makov-Assif, et al N Engl J Med April 13, 2022DOI: 10.1056/NEJMoa2201688 Abstract BACKGROUND With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine,...

ARTICLES|ONLINE FIRST Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalised adults with bloodstream infections: a multicentre, prospective, cohort study Evelina Tacconelli, Siri Göpel, Beryl P Gladstone, et al Lancet Infect Dis Published:January 19, 2022 DOI:https://doi.org/10.1016/S1473-3099(21)00587-9 Summary Background The burden of bloodstream infections remains high worldwide and cannot be confine...

ORIGINAL ARTICLE BNT162b2 Protection against the Omicron Variant in Children and Adolescents Ashley M. Price, Samantha M. Olson, Margaret M. Newhams, et al N Engl J Med March 30, 2022DOI: 10.1056/NEJMoa2202826 Abstract BACKGROUND Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion...

ARTICLES| VOLUME 22, ISSUE 2, P274-283, FEBRUARY 01, 2022 Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial Valentijn A Schweitzer, Inger van Heijl, Wim G Boersma, et al Lancet Infect Dis 2022; 22: 274-283 Summary Background Adults hospitalised to a non-intensive care unit (ICU) ward wit...

ORIGINAL ARTICLE Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia David J. Kuter, Merlin Efraim, Jiri Mayer, et al N Engl J Med 2022; 386:1421-1431DOI: 10.1056/NEJMoa2110297 Abstract BACKGROUND Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton’s tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)–mediated platelet de...

ORIGINAL ARTICLE Early Outpatient Treatment for Covid-19 with Convalescent Plasma David J. Sullivan, Kelly A. Gebo, Shmuel Shoham, et al N Engl J Med March 30, 2022DOI: 10.1056/NEJMoa2119657 Abstract BACKGROUND Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain. ...

ARTICLES|ONLINE FIRST Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis Willis S Bowman, Chad A Newton, Angela L Linderholm, et al Lancet Respir Med Published:January 18, 2022 DOI:https://doi.org/10.1016/S2213-2600(21)00503-8 Summary Background Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to...

ORIGINAL ARTICLE Tranexamic Acid in Patients Undergoing Noncardiac Surgery P.J. Devereaux, Maura Marcucci, Thomas W. Painter, et al N Engl J Med April 2, 2022DOI: 10.1056/NEJMoa2201171 Abstract BACKGROUND Perioperative bleeding is common in patients undergoing noncardiac surgery. Tranexamic acid is an antifibrinolytic drug that may safely decrease such bleeding. METHODS We conducted a trial involving patients undergoing noncardiac surgery. Patients...

ORIGINAL ARTICLE Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 Ariel Hammerman, Ruslan Sergienko, Michael Friger, et al N Engl J Med 2022; 386:1221-1229DOI: 10.1056/NEJMoa2119497 Abstract BACKGROUND The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decreases substantially among patients who have recovered from coronavirus disease 2019 (Covid-19). However, it is unknown how long protective immunit...

ARTICLES|ONLINE FIRST Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study Sue Ann Costa Clemens, Lily Weckx, Ralf Clemens, et al Lancet Published:January 21, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00094-0 Summary Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac...